Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Qiagen ( (QGEN) ).
Qiagen has disclosed that the Dutch financial markets regulator AFM notified the company of an updated substantial shareholding position held by U.S.-based asset manager BlackRock, Inc. The filing shows that BlackRock now holds a total capital interest of 10.66% and 11.83% of voting rights in Qiagen through a mix of real and potential positions, largely via various BlackRock subsidiaries.
The position is structured across ordinary shares and contracts for difference, with most of the interest held indirectly and a notable portion classified as potential holdings. The disclosure underscores BlackRock’s role as a major institutional investor in Qiagen, which may influence governance dynamics and signals continued large-scale institutional interest in the company’s stock.
The most recent analyst rating on (QGEN) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies used for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss venues, giving it broad access to international capital markets.
Average Trading Volume: 2,448,739
Technical Sentiment Signal: Sell
Current Market Cap: $8.27B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.